BioCentury | Aug 31, 2020
Deals

Three years after spinout, Ionis brings back Akcea in $500M acquisition

Three years after Ionis spun out its Akcea unit in an IPO, and nearly a year after the parent company installed a new CEO at the subsidiary, Ionis has chosen to retake full ownership of...
BioCentury | Aug 13, 2020
Regulation

Aug. 12 Quick Takes: Approvals for DMD, acute pain; plus Priority Review for Fabry, hypercholesterolemia therapies and more

FDA approves a second targeted DMD therapyNS Pharma Inc.’s Viltepso viltolarsen received accelerated approval from FDA to treat Duchenne muscular dystrophy in patients amenable to exon 53 skipping. Vyondys golodirsen from Sarepta Therapeutics Inc. (NASDAQ:SRPT) was the...
BioCentury | Jun 11, 2020
Finance

Insiders lead, crossovers join in gene editing play Verve’s $63M round

When gene editing company Verve went out seeking new investors for its latest round of funding, existing shareholder GV decided it would rather lead the round itself. GV and existing investors Arch Venture Partners, F-Prime...
BioCentury | Apr 11, 2020
Product Development

COVID-19 roundup: Lilly joins NIH’s adaptive trial; plus Foresee, Congress, ASCO, BMS, Otsuka, EC, Terumo-Marker

Eli Lilly’s rheumatoid arthritis drug Olumiant baricitinib has become the second treatment added to NIH’s COVID-19 master protocol, joining Gilead’s remdesivir. Separately, U.S. representatives called on FDA to ensure diagnostics are accurate, and ASCO launched...
BioCentury | Nov 27, 2019
Company News

With shares rising on M&A chatter, Arrowhead points to pipeline moves in 2020

Buoyed by news of this week's takeout of Medicines Co., Arrowhead is riding a wave of investor enthusiasm for RNAi therapeutics that has quintupled the company’s share price this year, and has boosted its valuation...
BioCentury | Oct 7, 2019
Company News

Amid management shakeup, Akcea strikes latest antisense deal

Akcea will bank $250 million up front from a new licensing deal with Pfizer, adding to a balance sheet already fattened by a February deal with Novartis for another antisense oligonucleotide program based on Akcea's...
BioCentury | Sep 7, 2019
Product Development

Regeneron’s evinacumab data could make it the therapy of choice in HoFH

With a cleaner safety profile and better efficacy than marketed agents, Regeneron’s first-in-class evinacumab is poised to become the standard of care for homozygous familial hypercholesterolemia and other rare lipid disorders, including for the hardest...
BioCentury | Aug 14, 2019
Clinical News

Regeneron data could set up first-in-class approval in lipid-lowering indication

Regeneron's evinacumab could give certain hypercholesterolemia patients a new treatment option, with an FDA submission looming based on new results from a Phase III trial evaluating the first-in-class therapy as an add-on to existing treatments....
BioCentury | May 7, 2019
Emerging Company Profile

Verve turns CRISPR against cardiovascular disease

Most CRISPR companies are targeting rare genetic disorders, but Verve is breaking from the trend with gene editing therapies for coronary artery disease that could have fewer side effects, greater efficacy and better compliance than...
BioCentury | Nov 2, 2018
Clinical News

Genentech's faricimab improves BCVA in Phase II for wet AMD

Genentech Inc. reported data from the Phase II STAIRWAY trial to treat wet age-related macular degeneration (AMD) showing that faricimab (RG7716) dosed every 12 or 16 weeks led to sustained improvements in visual outcomes that...
Items per page:
1 - 10 of 153